PRAXPraxis Precision Medicines, Inc.

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing precision therapies for central nervous system disorders characterized by neuronal excitability and excitation-inhibition imbalance. Praxis Precision Medicines, Inc. applies genetic and translational neuroscience insights to create treatments for movement disorders, epilepsy, and selected psychiatric and neurological conditions. Its portfolio includes both small-molecule programs and antisense oligonucleotide therapies, supported by proprietary research platforms designed to match drug candidates to specific biological targets and patient subgroups. The company’s work centers on disorders where shared neural circuitry and genetic mechanisms may help guide more targeted therapeutic development. Praxis Precision Medicines, Inc. operates as a research-driven biotech organization with a pipeline that spans multiple CNS indications and reflects a precision medicine approach to brain health.